Account wins

Share this article:
MedThink Communications has been retained by Salix Pharmaceuticals to launch and promote its newest product under development, an orally disintegrating form of metoclopramide. Salix recently licensed the rights to market the orally disintegrating metoclopramide tablet and will bring the drug to market following approval from the FDA. MedThink is also agency of record for several of Salix's gastrointestinal products, including the colonoscopy preparation OsmoPrep (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) and the targeted antibiotic Xifaxan (rifaximin).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions